Table 1.

Results from a BMD analysis of the data for different organs exposed to different type of PAHs and HCAs using BMD software version 3.1.2, a BMD of 10% and default settings based on assumption of equal potency of the selected PAHs and HCAs

Chemical	Gender	Duration	Type of disease	Model	BMDL10 (unit)	P-value	AIC
Fluoranthene (FA)	Ma	6 months	Lung adenoma	Logistic	0.175	0.46	47.03
	Fa			Gamma	0.17	0.70	48.25
	Ma	9 months		Dichotomous Hill	0.00	65535	68.08
	Fa			–	–	–	–
	Ma	6 months	Lung adenocarcinoma	Gamma	0.21	0.55	25.20
	Fa			Weibull	0.52	1.00	2.00
	Ma	9 months		Logistic	0.20	0.84	27.01
	Fa			Logistic	0.29	0.99	15.77
Benzo[a]pyrene (BaP)	Mb	104 weeks	Stomach cancer	–	–	–	–
	Fb			Quantal linear	2.68	0.99	147.33
	Mb		Liver cancer	Log-logistic	2.36	0.51	127.85
	Fb			Multistage degree 3	2.90	0.99	92.25
2-amino-3,8,dimethylimidazo[4,5-f]quinoxaline (MeIQx)	Mc	56 weeks	Liver cancer	Weibull	1.12	1.00	50.32
2-amino-1-methyl-6-phenylimidazo[4,5,6]pyridine (PhIP)	Md	104 weeks	Mammary cancer	–	–	–	–
	Fd			Logistic	0.77	0.75	124.42
	Md		Mammary cancer	Quantal linear	0.48	0.98	94.59
	Fd			Quantal linear	1.28	0.30	73.80
	Md		Colon cancer	Weibull	1.40	1.00	43.05
	Fd			Dichotomous hill	0.82	0.99	27.56

Notes: M = male; F = female;

^aWang & Busby (30);

^bAaslyng et al. (16);

^cKushida et al. (29);

^dCarthew et al. (28)